Company news
Akebia Therapeutics, Inc. news in 2022
Akebia Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Akebia Therapeutics Received Interim Response to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease from the FDA
December 21, 2022
Akebia Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference
November 21, 2022
Akebia Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 2, 2022
Akebia Therapeutics to Report Third Quarter Financial Results and Highlight Recent Company Milestones
October 26, 2022
Akebia Therapeutics Announces Poster Presentation at ASN Kidney Week 2022
October 20, 2022
Akebia Therapeutics to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference
August 31, 2022
Akebia Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
August 3, 2022
Akebia Therapeutics Announces Initial Findings from Investigator-Sponsored Clinical Study Evaluating Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Subjects with COVID-19 and Hypoxemia (VSTAT)
August 3, 2022
Akebia Therapeutics to Report Second Quarter Financial Results
July 25, 2022
Akebia Therapeutics Regaining Rights to Vadadustat in the United States, Europe, China and Access Consortium Countries upon Termination of Collaboration and License Agreements with Otsuka
June 29, 2022
Akebia Therapeutics Reports First Quarter 2022 Financial Results and Business Update
May 8, 2022
Akebia Therapeutics to Report First Quarter Financial Results
May 1, 2022
Akebia Therapeutics Announces Poster Presentations at National Kidney Foundation Spring Clinical Meetings 2022
April 5, 2022
Akebia Therapeutics Receives Complete Response Letter from the FDA for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients
March 29, 2022
Akebia Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Business Highlights
February 28, 2022
Akebia Therapeutics Announces Amendment of License Agreement with Vifor Pharma in Preparation for Potential Vadadustat Launch
February 21, 2022
Akebia Therapeutics to Report Fourth Quarter and Full-Year 2021 Financial Results and Discuss Recent Business Highlights
February 8, 2022
Akebia Therapeutics to Present at H.C. Wainwright Bioconnect Conference
January 9, 2022
Akebia Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
January 3, 2022